The heart has its own question
Human outcome trial · Published June 13, 2016
Can a weight chart answer a cardiovascular question?
Subject One brings the scale chart to a room full of clocks. “Wrong exhibit?” Doctide gives him a fresh sheet headed “Time to first event.” He folds the weight chart away. The visitor is following questions, not enrolling in another trial.
What changes here
LEADER favored liraglutide for its combined cardiovascular endpoint. [1]
Read the study details & dates
The heart has its own question
NCT01179048: reported double-blind trial of 9,340 people with type 2 diabetes and high cardiovascular risk; injected liraglutide versus placebo added to standard care. Median follow-up 3.8 years. First cardiovascular death, nonfatal heart attack or nonfatal stroke: 13.0% versus 14.9%; hazard ratio 0.87 (95% CI 0.78–0.97), superiority p=0.01. [1]
What this does not establish
Individual nonfatal heart attack, stroke and heart-failure hospitalization differences were not statistically significant. This population differs from the weight-management trial. Funding: Novo Nordisk and NIH.
Original sources
Reviewed November 10, 2026. Primary report; population-specific outcomes, not a universal cardiovascular promise.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story